JP Morgan Call 205 PSX 20.12.2024/ DE000JK4APS8 /
| 2024-06-27 8:44:45 AM | Chg.+0.001 | Bid12:13:24 PM | Ask12:13:24 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.100EUR | +1.01% | 0.110 Bid Size: 1,000 |
0.310 Ask Size: 1,000 |
Phillips 66 | 205.00 USD | 2024-12-20 | Call |
GlobeNewswire
12:00 PM
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Inte...
GlobeNewswire
06-26
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulat...
GlobeNewswire
06-25
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technolog...
GlobeNewswire
06-20
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Ris...
GlobeNewswire
06-17
Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2024 Earnings Conference Call
GlobeNewswire
06-17
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
06-12
Greystone Closes $22.9 Million in Total Debt Placement and Preferred Equity Financing for Fort Worth...
GlobeNewswire
06-05
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
05-29
Phillips Edison & Company to Present at Nareit REITweek 2024 Investor Conference
GlobeNewswire
05-22
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
GlobeNewswire
05-20
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease We...
GlobeNewswire
05-16
Optimal Daily Dairy Consumption Remains Elusive Despite Well-Established Health Benefits
GlobeNewswire
05-16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
